Amneal completes $750 million Kashiv BioSciences acquisition to create integrated biosimilars platform

The completed transaction combines Kashiv’s biologics R&D and manufacturing capabilities with Amneal’s commercial infrastructure, giving the company end-to-end control across biosimilar development, production and commercialisation.

Amneal Pharmaceuticals has completed its acquisition of 100% of Kashiv BioSciences, following an agreement providing for $375 million in cash and $375 million in equity at closing, plus up to $350 million in contingent regulatory milestone payments and potential commercial royalties.

The combination gives Amneal an integrated global biosimilars platform spanning research, development, manufacturing and commercialisation, with a portfolio intended to support multiple future biosimilar launches.

Field	Content
Alert Type	Deal
Companies	Amneal Pharmaceuticals; Kashiv BioSciences
Deal Type	Acquisition
Asset or Company	100% of Kashiv BioSciences
Therapy Area(s)	Multiple
Technology or Modality	Biosimilars; biologics development and manufacturing
Deal Value	The April 2026 acquisition agreement provided for $375 million in cash and $375 million in equity payable at closing, plus up to $350 million in potential regulatory milestone payments, potential royalties based on commercial milestones and funding of operations through closing. The additional $350 million and royalties are contingent and should not be treated as guaranteed consideration. (Amneal Pharmaceuticals)
Development Stage	Commercial and development-stage biosimilar portfolio
Geography	Global, with significant US operations and development and manufacturing capabilities in the US and India
What Happened	On 10 August 2026, Amneal announced completion of its acquisition of Kashiv BioSciences, following the definitive agreement announced on 22 April 2026. The transaction gives Amneal ownership of Kashiv’s biosimilar R&D, clinical, manufacturing, regulatory and intellectual-property capabilities, combining these operations with Amneal’s existing commercial infrastructure. Integration activities are now underway, focused on combining development and manufacturing capabilities and advancing the biosimilar pipeline. (BioSpace)
Why It Matters	The acquisition changes Amneal’s position in biosimilars from relying on partnerships and commercial capabilities to controlling a more vertically integrated platform spanning product development through manufacturing and commercialisation. Kashiv brings established biologics infrastructure, multiple commercial and advanced clinical-stage assets and experience obtaining marketing authorisations for biosimilars, potentially allowing Amneal to coordinate development and launches internally across a larger pipeline. (BioSpace)
Supporting Context	Amneal and Kashiv have worked together for more than a decade. At the time the transaction was announced, Amneal said the combined business was expected to have more than 12 commercial biosimilars and over 20 additional products in its pipeline by 2030, against a backdrop of more than $300 billion in projected global biologic loss of exclusivity over the coming decade. (Amneal Pharmaceuticals)
Strategic Rationale	Amneal gains Kashiv’s R&D and manufacturing infrastructure to complement its existing commercial scale, creating an end-to-end biosimilars operation. The integration is intended to support parallel development and commercialisation and a more consistent cadence of future biosimilar launches. (BioSpace)
Potential Impact	Successful integration could increase Amneal’s capacity to develop and launch biosimilars as major biologic products lose exclusivity. The extent of that impact will depend on successful pipeline development, regulatory approvals, manufacturing execution and commercial competition in individual biosimilar markets.
Key Takeaway	Completing the Kashiv acquisition gives Amneal an integrated biosimilars platform spanning R&D, manufacturing and commercialisation rather than simply adding individual biosimilar assets.
What to Watch	Integration of Kashiv’s development and manufacturing operations, progress of the combined biosimilar pipeline and whether Amneal achieves its planned cadence of multiple biosimilar launches each year. (BioSpace)
Primary Source	Amneal Pharmaceuticals completion announcement, 10 August 2026
Relevant Date	10 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com